April 17, 2019
The orphan drugs market is growing annually at roughly 7%. Total orphan drug sales will rise from $127bn for 2017 to $217bn in 2022.
An orphan drug can be defined as an agent specifically designed to treat rare (orphaned) diseases.
Prior to 1983 R&D of orphan drugs was limited but a US orphan drug act at that time gave incentive to the new development of these medicines.
NORD (The National Organization for Rare Disorders), one of the backers of the original act estimates 30 million Americans suffer from thousands of rare diseases.
The 1983 act paved way for other countries to follow suite, notably the European Union in 2000 and Japan a decade earlier.
The Pharma14, monthly updated, platform tracks and lists all marketing authorizations, including orphan drugs across 41 countries.
Sample data: Orphan drug Nitisinone in German market. 2 mg, 5 mg, 10 mg, 20 mg capsules.
April 02, 2019
March 26, 2019
March 19, 2019
March 12, 2019
March 05, 2019
February 26, 2019
February 19, 2019
February 12, 2019
February 05, 2019
January 29, 2019
January 22, 2019
January 15, 2019
January 08, 2019
January 01, 2019
December 25, 2018
December 18, 2018
Sample data: Japan Tadalafil still sold exclusively by Eli Lilly.
Sample data: Japan Pregabalin still sold exclusively by Pfizer.
December 11, 2018
Is one of your data needs and requirements the reimbursed status of medicines across Europe and other regulated markets?
Pharma14 is happy to announce the total coverage of reimbursed data of all medicines in our database.
As you know reimbursed information is one of those illusive data sets that can change on a constant basis.
Our monthly updated platform will give you total reimbursed information for over 500,000 marketed medicines across 41 countries.
60 Medinat Hayehudim St.
Entrance C. Third floor.